NEWS-LISEN lmprinting Diagnostics

NEWS

LisenID announces collaboration with Mayo Clinic to advance early cancer diagnostics

Wilmington, DE – Feb 13, 2025 – Lisen Imprinting Diagnostic, Inc. (LisenID) has entered a know-how agreement with Mayo Clinic to research and develop innovative early cancer diagnostic solutions.

Read More
Lisen Imprint Wins Delaware EDGE Competition Award

On November 20, 2024, the final list of winners for the Delaware EDGE (Encouraging Development, Growth & Expansion) competition was announced, with Lisen Imprint among the honorees.

Read More
Lisen Imprinting’s New Technology Eases Fear for HPV-Positive Patients

Breakthrough Published in Cancer Communications (IF=20.1): A Novel Early Cervical Cancer Detection Technology Developed by Lisen Imprinting and Sichuan University West China Second University Hospital

Read More
Lisen’s invention patent "MODEL, DIAGNOSTIC METHOD, AND APPLICATION THEREOF" about imprinted gene tumor early diagnosis technology was authorized by the European Patent Office！

Read More
Lisen’s Thyroid Cancer Diagnosis Research Published in the Journal of Clinical Oncology

Lisen's innovative epigenetics-based diagnostic solution for detecting thyroid cancers especially in cytologically indeterminate cases gets published in the Journal of Clinical Oncology.

Read More
Advancing Drug Development Innovation Through “Imprinted Genes + AI”

Lisen pursues scientific collaboration with Galixir by converging the technologies of both imprinted genes and artificial intelligence to revolutionize innovative drug development for lung cancer.

Read More
Lisen’s Lung Cancer Diagnosis Research Published in the Clinical Epigenetics Journal

Lisen's clinical research on leveraging the QCIGISH technology in the detection of early-stage lung cancer and small pulmonary nodules gets published in the Clinical Epigenetics journal.

Read More
Lisen’s QCIGISH Technology Published in the Clinical Epigenetics Journal

Lisen's collaborative research work on the development and application of the QCIGISH technology in the early detection of ten cancer types gets published in the Clinical Epigenetics journal.

Read More
Lisen Recognized Among Best Healthcare Startups by Merck

Lisen’s innovative technology was recognized as one of the top of the top six best Asian healthcare startups by Merck in its 2019 Accelerator Program in China.

Read More